EUVIMEDEUVIMED entdecken
Open Access

Cardiovascular Risk Factors and Genetic Risk in Transthyretin V142I Carriers

Naman S Shetty, Mokshad Gaonkar, Akhil Pampana, Nirav Patel, Alanna C Morrison, Alexander P Reiner, April P Carson, Bing Yu, Bruce M Psaty, Charles Kooperberg, Diane Fatkin, Eric Boerwinkle und 15 weitere

JACC: Heart Failure · 2025

DOI: 10.1016/j.jchf.2024.08.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Heart Failure, 2025. Verfasst von Naman S Shetty und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston…. Hauptthemen laut MEDLINE: Heart Disease Risk Factors, Heart Failure, Prealbumin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Nearly 3% to 4% of Black individuals in the United States carry the transthyretin V142I variant, which increases their risk of heart failure. However, the role of cardiovascular (CV) risk factors (RFs) in influencing the risk of clinical outcomes among V142I variant carriers is unknown. OBJECTIVES: This study aimed to assess the impact of CV RFs on the risk of heart failure in V142I carriers. METHODS: This study included self-identified Black individuals without prevalent heart failure from 6 TOPMed (Trans-Omics for Precision Medicine) cohorts, the REGARDS (Reasons for Geographic And Racial Differences in Stroke) study, and the All of Us Research Program. The cohort was stratified based on the V142I genotype and the number of CV RFs (hypertension, diabetes, obesity, and hypercholesterolemia). Adjusted Cox models were used to assess the association of heart failure with the V142I genotype and CV RF profile, taking noncarriers with a favorable CV RF profile as reference. RESULTS: The cross-sectional analysis, including 1,625 V142I carriers among 48,365 Black individuals, found that the prevalence of CV RFs did not vary by V142I carrier status. In the longitudinal analysis, there were 587 (3.2%) V142I carriers among 18,407 Black individuals (median age: 60 years [Q1-Q3: 52-68 years], 63.0% female). Among carriers, the heart failure risk was attenuated with a favorable (0 or 1 RF) CV RF profile (adjusted HR: 2.26; 95% CI: 1.58-3.23) compared with an unfavorable (3 or 4 RFs) CV RF profile (adjusted HR: 4.14; 95% CI: 2.79-6.14). CONCLUSIONS: A favorable CV RF profile lowers but does not abrogate V142I variant-associated heart failure risk. This study highlights the importance of having a favorable CV RF profile among V142I carriers for risk reduction of heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Disease Risk FactorsHeart FailurePrealbuminAgedFemaleHumansMaleMiddle AgedBlack or African AmericanCardiovascular DiseasesCross-Sectional StudiesDiabetes MellitusGenotypeHeterozygoteHypercholesterolemiaHypertensionObesityRisk FactorsUnited States

Stichwörter der Autor:innen

Black individualsV142Iamyloidosiscardiovascular risk factorsheart failuremortality

Substanzen

PrealbuminTTR protein, human

Autor:innen und Institutionen

  • Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Human Genetics Center, University of Texas Health Science Center, Houston, Texas, USA.
  • Department of Epidemiology, University of Washington, Seattle, Washington, USA; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
  • Department of Epidemiology, University of Washington, Seattle, Washington, USA; Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA; Department of Health Syste…

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health

Zitieren

APA

Shetty, N. S., Gaonkar, M., Pampana, A., Patel, N., Morrison, A. C., Reiner, A. P., Carson, A. P., Yu, B., Psaty, B. M., Kooperberg, C., Fatkin, D., Boerwinkle, E., Rotter, J. I., Taylor, K. D., Hou, L., Irvin, M. R., Hall, M. E., Maurer, M., Fornage, M., …, & Arora, P. (2025). Cardiovascular Risk Factors and Genetic Risk in Transthyretin V142I Carriers. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2024.08.019

Vancouver

Shetty NS, Gaonkar M, Pampana A, Patel N, Morrison AC, Reiner AP, et al. Cardiovascular Risk Factors and Genetic Risk in Transthyretin V142I Carriers. JACC: Heart Failure. 2025. doi:10.1016/j.jchf.2024.08.019

BibTeX
@article{Shetty2025,
  author = {Shetty, Naman S and Gaonkar, Mokshad and Pampana, Akhil and Patel, Nirav and Morrison, Alanna C and Reiner, Alexander P and Carson, April P and Yu, Bing and Psaty, Bruce M and Kooperberg, Charles and Fatkin, Diane and Boerwinkle, Eric and Rotter, Jerome I and Taylor, Kent D and Hou, Lifang and Irvin, Marguerite R and Hall, Michael E and Maurer, Mathew and Fornage, Myriam and Armstrong, Nicole D and Bart, Nicole and Goyal, Parag and Rich, Stephen S and Vasan, Ramachandran S and Li, Peng and Arora, Garima and Arora, Pankaj},
  title = {Cardiovascular Risk Factors and Genetic Risk in Transthyretin V142I Carriers},
  journal = {JACC: Heart Failure},
  year = {2025},
  doi = {10.1016/j.jchf.2024.08.019}
}
Kostenlos starten →